[go: up one dir, main page]

DE69620639D1 - Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) - Google Patents

Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)

Info

Publication number
DE69620639D1
DE69620639D1 DE69620639T DE69620639T DE69620639D1 DE 69620639 D1 DE69620639 D1 DE 69620639D1 DE 69620639 T DE69620639 T DE 69620639T DE 69620639 T DE69620639 T DE 69620639T DE 69620639 D1 DE69620639 D1 DE 69620639D1
Authority
DE
Germany
Prior art keywords
necrosis factor
mmp
tnf
inhibitors
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620639T
Other languages
English (en)
Other versions
DE69620639T2 (de
Inventor
Andrew Douglas Baxter
John Gary Montana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523828.3A external-priority patent/GB9523828D0/en
Priority claimed from GBGB9607121.2A external-priority patent/GB9607121D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DE69620639D1 publication Critical patent/DE69620639D1/de
Publication of DE69620639T2 publication Critical patent/DE69620639T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69620639T 1995-11-22 1996-11-22 Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) Expired - Fee Related DE69620639T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9523828.3A GB9523828D0 (en) 1995-11-22 1995-11-22 Compounds
GBGB9607121.2A GB9607121D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/002892 WO1997019075A1 (en) 1995-11-22 1996-11-22 Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
DE69620639D1 true DE69620639D1 (de) 2002-05-16
DE69620639T2 DE69620639T2 (de) 2002-10-17

Family

ID=26308152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620639T Expired - Fee Related DE69620639T2 (de) 1995-11-22 1996-11-22 Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)

Country Status (19)

Country Link
US (1) US6048841A (de)
EP (1) EP0874842B1 (de)
JP (1) JP2000500482A (de)
KR (1) KR19990067687A (de)
CN (1) CN1072667C (de)
AT (1) ATE215946T1 (de)
AU (1) AU711907B2 (de)
BR (1) BR9611636A (de)
CA (1) CA2229438C (de)
CZ (1) CZ291337B6 (de)
DE (1) DE69620639T2 (de)
ES (1) ES2172690T3 (de)
HU (1) HUP9904131A3 (de)
IL (1) IL123431A (de)
MX (1) MX9804052A (de)
NO (1) NO982290L (de)
NZ (1) NZ322565A (de)
PL (1) PL326710A1 (de)
WO (1) WO1997019075A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
RU2201931C2 (ru) 1996-11-20 2003-04-10 Биомежер Инкорпорэйтед Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы
WO2001087849A2 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
KR100980163B1 (ko) * 2002-01-07 2010-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 데아자퓨린 및 이의 용도
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1562571B1 (de) * 2002-11-21 2011-08-17 Genzyme Corporation Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
EP1567138B1 (de) * 2002-11-21 2011-01-05 Genzyme Corporation Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
PL227790B1 (pl) 2015-08-13 2018-01-31 Slaski Univ Medyczny W Katowicach Fosfoniany acetylenowych pochodnych betuliny o działaniu przeciwnowotworowym, sposób ich wytwarzania i zastosowanie.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
ATE179431T1 (de) * 1994-10-05 1999-05-15 Darwin Discovery Ltd Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren

Also Published As

Publication number Publication date
ES2172690T3 (es) 2002-10-01
CZ145598A3 (cs) 1998-08-12
KR19990067687A (ko) 1999-08-25
HUP9904131A2 (hu) 2000-06-28
MX9804052A (es) 1998-09-30
CA2229438A1 (en) 1997-05-29
EP0874842B1 (de) 2002-04-10
AU7634396A (en) 1997-06-11
IL123431A (en) 2001-05-20
CZ291337B6 (cs) 2003-02-12
EP0874842A1 (de) 1998-11-04
AU711907B2 (en) 1999-10-21
DE69620639T2 (de) 2002-10-17
NO982290D0 (no) 1998-05-20
PL326710A1 (en) 1998-10-26
HUP9904131A3 (en) 2002-04-29
CN1202895A (zh) 1998-12-23
CN1072667C (zh) 2001-10-10
US6048841A (en) 2000-04-11
CA2229438C (en) 2006-01-17
NZ322565A (en) 1999-11-29
WO1997019075A1 (en) 1997-05-29
JP2000500482A (ja) 2000-01-18
IL123431A0 (en) 1998-09-24
ATE215946T1 (de) 2002-04-15
BR9611636A (pt) 1999-12-28
NO982290L (no) 1998-05-20

Similar Documents

Publication Publication Date Title
DE69620639D1 (de) Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
WO1993021942A3 (en) Use of mmp inhibitors
BR9509237A (pt) Compostos peptidila e seu uso terapêutico como inibidores de metaloproteases
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
NO992337L (no) Bicykliske arylkarboksamider og deres terapeutiske anvendelse
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
DE69835518D1 (de) Imidazolyl-cyclische acetale
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
ATE239477T1 (de) Chinolone und deren therapeutische verwendung
ATE346600T1 (de) Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
BR9805544A (pt) Uso de um composto.
AU3738393A (en) Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
IL122782A (en) Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same
BG103832A (en) Leptin as tumour cells proliferation inhibitor
ES2000734A6 (es) Un procedimiento para la preparacion de pirimidinas
GR3029490T3 (en) Use of leflunomid for the inhibition of tumor necrosis factor alpha.
DE69627483D1 (de) Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE275955T1 (de) Verwendung von phospholambanhemmer zur steigerung der koronäre durchblutung
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
ATE215935T1 (de) Heterozyklische verbidungen mit mmp und tnf inhibitorisher wirkung

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee